通过法律意见及咨询评估您的知识产权资产
我们每年提供数百条法律意见,从针对具体专利的单一意见,到提供关于复杂专利组合或诉讼的长期、持续咨询服务。我们为客户解决专利有效性、可执行性、滥用、回避设计、许可潜力、知识产权合同构建和执行、以及出口管制等问题。我们定期与客户的法律、业务和技术人员合作,确认从创意产生到专利组合开始盈利整个过程中的潜在风险和收益。
除交易咨询服务外,我们还长期向客户提供诉讼前策略建议。我们拥有丰富的诉讼经验,能够直接洞察诉讼对手可能提出的各种论据。凭借诉讼和知识产权交易的双重经验,我们能够帮助客户在诉讼前或诉讼中有利解决纠纷。
Filed an amicus brief on behalf of non-parties Toyota Motor Corporation, Honda Motor Company, Nissan Motor Company, DENSO Corporation, and Hyundai Motor Company in a Federal Circuit appeal involving issues related to standard-essential patents.
18-1363, -1380, -1382, -1732, Fed. Cir., Judges Newman, Chen, Hughes
Finnegan prepared and prosecuted patents for startup Hutchison Medipharma in the United States for the treatment of metastatic colorectal cancer. Those patents cover a small molecule, fruquintinib, which received approval in China.
Finnegan successfully generated patents to cover protease inhibitor Viracept®, for then startup company Agouron Pharmaceuticals, Inc. Agouron was ultimately acquired by Warner-Lambert (now part of Pfizer) based on the strength of the Viracept® patents, for $2.1 billion.
Webinar
January 11, 2024
Webinar
Seminar
September 5, 2023
Tel Aviv
IP Updates
Senate Legislation Proposes Changes to Patent Eligibility and PTAB Proceedings
June 27, 2023
Webinar
June 16, 2022
Webinar
Commentary
How I Made Partner: Finnegan's Danielle Duszczyszyn Shares Six Keys to Business Development Success
December 16, 2020
Charles T. Collins-Chase
Esther H. Lim Nominated as Candidate for President-Elect of the D.C. Bar
March 6, 2017
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.